Aditya Bardia, MD, MPH - Keeping to Target in mTNBC: Optimising Outcomes With Antibody-Drug Conjugates in Practice

Visit https://www.peervoice.com/WQS860 to view the entire programme with slides. After completing “Aditya Bardia, MD, MPH - Keeping to Target in mTNBC: Optimising Outcomes With Antibody-Drug Conjugates in Practice”, participants will be able to: Recognise the toxicity profile of antibody-drug conjugates (ADCs) for metastatic triple-negative breast cancer (mTNBC) and when they are most likely to occur; Propose practical approaches to mitigating and/or managing the toxicity profile of ADCs in patients with mTNBC; and Discuss the importance of an effective multidisciplinary team and patient communication and collaboration in treatment optimisation for patients with mTNBC who are receiving an ADC.